Therapeutic efficacy and safety of supplementing ACE2 and Ang (1‐7) with this existing product in non‐critically ill COVID‐19 patients in the hospital and at home is in progress.
By employing an integrated Phase 1 and Phase 2 clinical trial design, this clinical trial addresses an urgent unmet medical need to treat the growing population of COVID‐19 patients and protect them from lung and extra‐pulmonary tissue injury.